TENAYA and LUCERNE

Purpose: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the first bispecific antibody for intraocular use, whic...

Full description

Bibliographic Details
Main Authors:	Arshad M. Khanani, MD, MA, Robyn H. Guymer, MD, PhD, Karen Basu, PhD, Heather Boston, MSc, Jeffrey S. Heier, MD, Jean-François Korobelnik, MD, Aachal Kotecha, PhD, Hugh Lin, MD, MBA, David Silverman, MBChB, MRCOphth, Balakumar Swaminathan, MSc, Jeffrey R. Willis, MD, PhD, Young Hee Yoon, MD, PhD, Carlos Quezada-Ruiz, MD
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	Ophthalmology Science
Subjects:	Anti-VEGF therapy Faricimab Neovascular age-related macular degeneration Personalized treatment interval
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666914521000774

Internet

http://www.sciencedirect.com/science/article/pii/S2666914521000774

TENAYA and LUCERNE

Internet

Similar Items